China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Up 48.3% in July

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 72,800 shares, agrowthof48.3% from the July 15th total of 49,100 shares. Currently,0.1% of the shares of the company are sold short. Based on an average trading volume of 568,100 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 568,100 shares, the days-to-cover ratio is currently 0.1 days. Currently,0.1% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of China SXT Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd.

China SXT Pharmaceuticals Trading Up 1.6%

Shares of SXTC opened at $1.63 on Tuesday. The stock has a fifty day moving average price of $1.71 and a two-hundred day moving average price of $2.28. China SXT Pharmaceuticals has a 52-week low of $0.95 and a 52-week high of $8.48. The company has a current ratio of 3.54, a quick ratio of 3.40 and a debt-to-equity ratio of 0.01.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.